Oral azacitidine combination meets Phase 3 drug exposure endpoint; Taiho plans FDA filing

For patients with hematologic malignancies who require repeated injections, oral medication could reduce the burden of traveling to and from healthcare facilities—provided that the body still receives the required drug exposure after the route of administration changes. Taiho Pharmaceutical and Taiho Oncology announced that ASTX030, an oral combination of azacitidine and cedazuridine, met the primary endpoint in the Phase 3 AZTOUND trial in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), providing a basis for a subsequent application for marketing approval.

Taiho Oncology released the results on September 30, and its Japanese parent company issued an announcement on October 1. The Phase 3 study enrolled 88 adults and used a randomized, open-label crossover design. According to Targeted Oncology's description of the trial procedures, patients received oral ASTX030 in the first treatment cycle and switched to subcutaneous azacitidine in the second, or received the treatments in the reverse order. From the third cycle onward, all patients received ASTX030. This allowed researchers to compare the two routes of administration within the same patient.

The primary endpoint compared cumulative azacitidine exposure over an entire treatment cycle, calculating the ratio of oral to subcutaneous exposure using the area under the blood concentration–time curve (AUC) from 0 to 24 hours after each dose. AUC can be understood as the total amount of drug exposure the body receives over a period of time. The companies said the study met its endpoint, but have not disclosed the actual Phase 3 ratio, confidence interval, or prespecified range for meeting the endpoint. It is therefore not yet possible to independently assess from the announcement how closely the two routes of administration compare.

The key to this oral strategy is that the two components play different roles. Azacitidine is a DNA methyltransferase inhibitor; cedazuridine inhibits cytidine deaminase, helping reduce the breakdown of azacitidine so that the drug remains active in the body. The combination is designed to address whether oral administration can achieve the required exposure, rather than simply converting an injectable drug into another dosage form.

Meeting the drug exposure endpoint still cannot be directly translated into longer survival or better disease control for patients. The announcement provides a summary of the primary results, without full data sufficient to compare treatment response, survival, or quality of life. Oral administration may reduce the time burden associated with injections, but how much it could improve patients' lives also requires corresponding clinical evidence.

On safety, the two companies said ASTX030's profile was consistent with that of injectable azacitidine, but the announcement did not list the incidence or severity of individual adverse events or treatment discontinuations. This description provides preliminary information, but does not establish that oral treatment is safer. A more detailed assessment of its risks will be possible once the full results are released.

Taiho Oncology plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) based on the trial results and to submit the data for presentation at an international medical conference. The announcement did not specify a filing date. ASTX030 remains investigational and has not been approved by any health authority. For patients, this represents a step forward in the development of oral treatment; whether it becomes an available treatment option will still depend on the full evidence and regulatory review.